Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway

• Main Authors: Yilan Huang (Author), Siwei Wang (Author), Xiaojun Zhang (Author), Chen Yang (Author), Sikai Wang (Author), Hongxia Cheng (Author), Aiwu Ke (Author), Chao Gao (Author), Kun Guo (Author)
• Format: Book
• Published: Elsevier, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Lenvatinib is a frontline tyrosine kinase inhibitor for patients with advanced hepatocellular carcinoma (HCC). However, just 25% of patients benefit from the treatment, and acquired resistance always develops. To date, there are neither effective medications to combat lenvatinib resistance nor accur...